Schedule of the Consolidated Changes in Equity |
Consolidated Changes in Equity (amounts in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bio-Techne Shareholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
Other |
|
|
|
|
|
Common Stock |
|
Paid-in |
|
Retained |
|
Comprehensive |
|
|
|
|
Shares |
|
Amount |
|
Capital |
|
Earnings |
|
Loss |
|
Total |
Balances at June 30, 2024 |
|
158,216 |
|
$ |
1,582 |
|
$ |
820,337 |
|
$ |
1,325,247 |
|
$ |
(78,316) |
|
$ |
2,068,850 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
33,600 |
|
|
|
|
|
33,600 |
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
18,229 |
|
|
18,229 |
Common stock issued for exercise of options |
|
577 |
|
|
6 |
|
|
23,224 |
|
|
(2,338) |
|
|
|
|
|
20,892 |
Common stock issued for restricted stock awards |
|
50 |
|
|
1 |
|
|
1 |
|
|
(2,646) |
|
|
|
|
|
(2,644) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,688) |
|
|
|
|
|
(12,688) |
Stock-based compensation expense |
|
|
|
|
|
|
|
10,146 |
|
|
|
|
|
|
|
|
10,146 |
Common stock issued to employee stock purchase plan |
|
35 |
|
|
0 |
|
|
2,227 |
|
|
|
|
|
|
|
|
2,227 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
38 |
|
|
|
|
|
|
|
|
38 |
Balances at September 30, 2024 |
|
158,878 |
|
$ |
1,589 |
|
$ |
855,973 |
|
$ |
1,341,175 |
|
$ |
(60,087) |
|
$ |
2,138,650 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
34,890 |
|
|
|
|
|
34,890 |
Other comprehensive (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
(25,563) |
|
|
(25,563) |
Share repurchases |
|
(1,118) |
|
|
(11) |
|
|
|
|
|
(75,617) |
|
|
|
|
|
(75,628) |
Common stock issued for exercise of options |
|
132 |
|
|
1 |
|
|
5,183 |
|
|
(20) |
|
|
|
|
|
5,164 |
Common stock issued for restricted stock awards |
|
24 |
|
|
0 |
|
|
0 |
|
|
(993) |
|
|
|
|
|
(993) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,736) |
|
|
|
|
|
(12,736) |
Stock-based compensation expense |
|
|
|
|
|
|
|
14,335 |
|
|
|
|
|
|
|
|
14,335 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
373 |
|
|
|
|
|
|
|
|
373 |
Balances at December 31, 2024 |
|
157,916 |
|
$ |
1,579 |
|
$ |
875,864 |
|
$ |
1,286,699 |
|
$ |
(85,650) |
|
$ |
2,078,492 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
22,588 |
|
|
|
|
|
22,588 |
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
3,598 |
|
|
3,598 |
Share repurchases |
|
(1,489) |
|
|
(15) |
|
|
|
|
|
(100,031) |
|
|
|
|
|
(100,046) |
Common stock issued for exercise of options |
|
282 |
|
|
3 |
|
|
12,628 |
|
|
|
|
|
|
|
|
12,631 |
Common stock issued for restricted stock awards |
|
9 |
|
|
1 |
|
|
1 |
|
|
(291) |
|
|
|
|
|
(289) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,580) |
|
|
|
|
|
(12,580) |
Stock-based compensation expense |
|
|
|
|
|
|
|
11,355 |
|
|
|
|
|
|
|
|
11,355 |
Common stock issued to employee stock purchase plan |
|
43 |
|
|
0 |
|
|
2,241 |
|
|
|
|
|
|
|
|
2,241 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
35 |
|
|
|
|
|
|
|
|
35 |
Balances at March 31, 2025 |
|
156,761 |
|
$ |
1,568 |
|
$ |
902,124 |
|
$ |
1,196,385 |
|
$ |
(82,052) |
|
$ |
2,018,025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bio-Techne Shareholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
Other |
|
|
|
|
|
Common Stock |
|
Paid-in |
|
Retained |
|
Comprehensive |
|
|
|
|
|
Shares |
|
Amount |
|
Capital |
|
Earnings |
|
Loss |
|
Total |
Balances at June 30, 2023 |
|
157,642 |
|
$ |
1,576 |
|
$ |
721,543 |
|
$ |
1,309,461 |
|
$ |
(66,064) |
|
$ |
1,966,516 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
50,993 |
|
|
|
|
|
50,993 |
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,952) |
|
|
(11,952) |
Common stock issued for exercise of options |
|
633 |
|
|
6 |
|
|
12,877 |
|
|
(15,460) |
|
|
|
|
|
(2,577) |
Common stock issued for restricted stock awards |
|
47 |
|
|
1 |
|
|
0 |
|
|
(4,768) |
|
|
|
|
|
(4,767) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,654) |
|
|
|
|
|
(12,654) |
Stock-based compensation expense |
|
|
|
|
|
|
|
9,981 |
|
|
|
|
|
|
|
|
9,981 |
Common stock issued to employee stock purchase plan |
|
33 |
|
|
1 |
|
|
2,093 |
|
|
|
|
|
|
|
|
2,094 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
112 |
|
|
|
|
|
|
|
|
112 |
Balances at September 30, 2023 |
|
158,355 |
|
$ |
1,584 |
|
$ |
746,606 |
|
$ |
1,327,572 |
|
$ |
(78,016) |
|
$ |
1,997,746 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
27,465 |
|
|
|
|
|
27,465 |
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
14,355 |
|
|
14,355 |
Share repurchases |
|
(1,397) |
|
|
(14) |
|
|
|
|
|
(80,028) |
|
|
|
|
|
(80,042) |
Common stock issued for exercise of options |
|
157 |
|
|
1 |
|
|
4,914 |
|
|
(1,074) |
|
|
|
|
|
3,841 |
Common stock issued for restricted stock awards |
|
27 |
|
|
0 |
|
|
0 |
|
|
|
|
|
|
|
|
0 |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,559) |
|
|
|
|
|
(12,559) |
Stock-based compensation expense |
|
|
|
|
|
|
|
12,413 |
|
|
|
|
|
|
|
|
12,413 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
340 |
|
|
|
|
|
|
|
|
340 |
Balances at December 31, 2023 |
|
157,142 |
|
$ |
1,571 |
|
$ |
764,273 |
|
$ |
1,261,376 |
|
$ |
(63,661) |
|
$ |
1,963,559 |
Net earnings |
|
|
|
|
|
|
|
|
|
|
49,059 |
|
|
|
|
|
49,059 |
Other comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
(11,646) |
|
|
(11,646) |
Common stock issued for exercise of options |
|
372 |
|
|
4 |
|
|
15,761 |
|
|
|
|
|
|
|
|
15,765 |
Common stock issued for restricted stock awards |
|
4 |
|
|
0 |
|
|
0 |
|
|
(168) |
|
|
|
|
|
(168) |
Cash dividends |
|
|
|
|
|
|
|
|
|
|
(12,579) |
|
|
|
|
|
(12,579) |
Stock-based compensation expense |
|
|
|
|
|
|
|
8,053 |
|
|
|
|
|
|
|
|
8,053 |
Common stock issued to employee stock purchase plan |
|
36 |
|
|
1 |
|
|
2,251 |
|
|
|
|
|
|
|
|
2,252 |
Employee stock purchase plan expense |
|
|
|
|
|
|
|
80 |
|
|
|
|
|
|
|
|
80 |
Balances at March 31, 2024 |
|
157,554 |
|
$ |
1,576 |
|
$ |
790,418 |
|
$ |
1,297,688 |
|
$ |
(75,307) |
|
$ |
2,014,375 |
|
Schedule of changes in Accumulated Other Comprehensive Income (Loss) |
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2025 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of December 31, 2024, net of tax |
|
$ |
5,030 |
|
$ |
(90,680) |
|
$ |
(85,650) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(3,079) |
|
|
4,807 |
|
|
1,728 |
Amounts reclassified out |
|
|
1,790 |
|
|
660 |
|
|
2,450 |
Total other comprehensive income (loss), before tax |
|
|
(1,289) |
|
|
5,467 |
|
|
4,178 |
Tax (expense)/benefit |
|
|
(424) |
|
|
(156) |
|
|
(580) |
Total other comprehensive income (loss), net of tax |
|
|
(1,713) |
|
|
5,311 |
|
|
3,598 |
Balance as of March 31, 2025, net of tax |
|
$ |
3,317 |
|
$ |
(85,369) |
|
$ |
(82,052) |
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2024 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of December 31, 2023 net of tax: |
|
$ |
8,842 |
|
$ |
(72,503) |
|
$ |
(63,661) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(1,626) |
|
|
(12,620) |
|
|
(14,246) |
Amounts reclassified out |
|
|
2,570 |
|
|
837 |
|
|
3,407 |
Total other comprehensive income (loss), before tax |
|
|
944 |
|
|
(11,783) |
|
|
(10,839) |
Tax (expense)/benefit |
|
|
(609) |
|
|
(198) |
|
|
(807) |
Total other comprehensive income (loss), net of tax |
|
|
335 |
|
|
(11,981) |
|
|
(11,646) |
Balance as of March 31, 2024, net of tax |
|
$ |
9,177 |
|
$ |
(84,484) |
|
$ |
(75,307) |
|
|
|
|
|
|
|
|
|
|
Nine months ended March 31, 2025 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of June 30, 2024, net of tax: |
|
$ |
8,102 |
|
$ |
(86,418) |
|
$ |
(78,316) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(9,778) |
|
|
(555) |
|
|
(10,333) |
Amounts reclassified out |
|
|
6,544 |
|
|
2,102 |
|
|
8,646 |
Total other comprehensive income (loss), before tax |
|
|
(3,234) |
|
|
1,547 |
|
|
(1,687) |
Tax (expense)/benefit |
|
|
(1,551) |
|
|
(498) |
|
|
(2,049) |
Total other comprehensive income (loss), net of tax |
|
|
(4,785) |
|
|
1,049 |
|
|
(3,736) |
Balance as of March 31, 2025, net of tax(1) |
|
$ |
3,317 |
|
$ |
(85,369) |
|
$ |
(82,052) |
|
|
|
|
|
|
|
|
|
|
Nine months ended March 31, 2024 (in thousands): |
|
Unrealized |
|
|
|
|
|
|
|
|
Gains |
|
Foreign |
|
|
|
|
|
(Losses) on |
|
Currency |
|
|
|
|
|
Derivative |
|
Translation |
|
|
|
|
|
Instruments |
|
Adjustments |
|
Total |
Balance as of June 30, 2023, net of tax: |
|
$ |
12,862 |
|
$ |
(78,926) |
|
$ |
(66,064) |
Other comprehensive income (loss), before tax: |
|
|
|
|
|
|
|
|
|
Amounts before reclassifications |
|
|
(9,582) |
|
|
(7,368) |
|
|
(16,950) |
Amounts reclassified out |
|
|
7,729 |
|
|
2,372 |
|
|
10,101 |
Total other comprehensive income (loss), before tax |
|
|
(1,853) |
|
|
(4,996) |
|
|
(6,849) |
Tax (expense)/benefit |
|
|
(1,832) |
|
|
(562) |
|
|
(2,394) |
Total other comprehensive income (loss), net of tax |
|
|
(3,685) |
|
|
(5,558) |
|
|
(9,243) |
Balance as of March 31, 2024, net of tax(1) |
|
$ |
9,177 |
|
$ |
(84,484) |
|
$ |
(75,307) |
(1) The Company had a net deferred tax liability for its cash flow hedge of $1.0 million and $2.9 million as of March 31, 2025 and 2024, respectively.
|